What insurance policy changes affect code T78.01XA?

There are 2 tracked policy changes affecting code T78.01XA, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code T78.01XA?

Payers that have issued tracked updates for code T78.01XA include: Aetna.

How do I get notified when code T78.01XA policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code T78.01XA. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code T78.01XA?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

T78.01XA Insurance Policy Changes

ICD-10 T78.01XA is officially defined as "Anaphylactic reaction due to peanuts, initial encounter." code T78.01XA is referenced in 2 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code T78.01XA is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Only a small number of policies match this filter. Check back as coverage expands.

Aetna · Identified Sep 30, 2026Medium impact
Peanut Immunotherapy (CPB 0968, reviewed 2026-08-21)
Aetna considers oral Palforzia (peanut allergen powder-dnfp) medically necessary to mitigate allergic reactions, including anaphylaxis, in members with a confirmed peanut allergy when all initial approval criteria are met, including use with a peanut-avoidant diet, no uncontrolled asthma, no history of eosinophilic esophagitis or other eosinophilic gastrointestinal disease, and age 1 to 17 years for initial dose escalation or age 1 year and older for up-dosing or maintenance. Co-administration of Palforzia with a monoclonal antibody such as omalizumab, and Palforzia for the emergency treatment of allergic reactions, are considered experimental, investigational, or unproven, as are all other indications. The policy also states that the Initial Dose Escalation and the first dose of each Up-Dosing level must be given in a healthcare setting equipped to monitor members and manage anaphylaxis.
Aetna · Identified Aug 13, 2026Medium impact
Peanut Immunotherapy (CPB 0968, reviewed 2026-05-27)
Aetna considers oral Palforzia medically necessary to mitigate allergic reactions, including anaphylaxis, in members with a confirmed peanut allergy when specific criteria are met. The criteria cover confirmation of the diagnosis by serum IgE level or skin prick test, use with a peanut-avoidant diet, and exclusion of uncontrolled asthma, a history of eosinophilic esophagitis, or other eosinophilic gastrointestinal disease. Members must be 1 to 17 years of age for initial dose escalation, or 1 year of age or older for up-dosing or maintenance. Aetna considers all other indications experimental, investigational, or unproven, along with co-administration with a monoclonal antibody such as omalizumab and use for emergency treatment of allergic reactions.

Watch T78.01XA

Get one email when a payer policy names T78.01XA, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Peanut Immunotherapy (CPB 0968, reviewed 2026-08-21)

Peanut Immunotherapy (CPB 0968, reviewed 2026-05-27)

What insurance policy changes affect code T78.01XA?

Which payers have updated policy for code T78.01XA?

How do I get notified when code T78.01XA policy changes?

Why do payers change policies for code T78.01XA?